This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lacoma, A.
Right arrow Articles by Domínguez, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lacoma, A.
Right arrow Articles by Domínguez, J.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, November 2008, p. 3660-3667, Vol. 46, No. 11
0095-1137/08/$08.00+0     doi:10.1128/JCM.00618-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

GenoType MTBDRplus Assay for Molecular Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Strains and Clinical Samples{triangledown}

A. Lacoma,1 N. Garcia-Sierra,1 C. Prat,1,3 J. Ruiz-Manzano,2,3 L. Haba,1 S. Rosés,1 J. Maldonado,4 and J. Domínguez1,3*

Servei de Microbiologia,1 Servei de Pneumologia, Hospital Universitari Germans Trias i Pujol, Fundació Institut d'Investigació en Ciències de la Salut, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain,2 Ciber Enfermedades Respiratorias, Instituto de Salud Carlos III, Badalona, Spain,3 Serveis Clínics de Barcelona, Barcelona, Spain4

Received 1 April 2008/ Returned for modification 17 June 2008/ Accepted 7 August 2008

The purpose of this study was to evaluate the GenoType MTBDRplus assay (Hain Lifescience GmbH, Nehren, Germany) for its ability to detect resistance to rifampin (RIF) and isoniazid (INH) in Mycobacterium tuberculosis clinical strains and directly in clinical samples. A total of 62 clinical strains characterized with the Bactec 460TB system were included. For the INH-resistant strains, the MIC was measured and sequencing was performed. Sixty-five clinical samples from 28 patients (39 smear-positive samples and 26 smear-negative samples) were also tested directly. The corresponding isolates of the clinical specimens were studied with the Bactec 460TB system. The overall rates of concordance of the MTBDRplus assay and the Bactec 460TB system for the detection of RIF and INH susceptibility in clinical strains were 98.3% (61/62) and 79% (49/62), respectively. The rate of concordance between the Bactec 460TB system and the MTBDRplus test for the detection of INH resistance in the group of 27 strains with low-level resistance was 62.9% (17/27), and that for the detection of INH resistance in the group of 21 strains with high-level resistance was 85.71% (18/21). Valid test results were obtained for 78.45% (51/65) of the clinical samples tested. The rates of concordance between both assays for the detection of drug resistance in these samples were 98% (50/51) for RIF and 96.2% (49/51) for INH. Taking into account only one sample per patient, the overall rate of concordance between both tests was 92.85% (26/28). The GenoType MTBDRplus assay is easy to perform and is a useful tool for the management of tuberculosis, as it allows the detection of resistance to RIF and INH in M. tuberculosis strains and also in clinical samples.

* Corresponding author. Mailing address: Servei de Microbiologia, Fundació Institut en Ciències de la Salut Germans Trias i Pujol, Carretera del Canyet s/n, Badalona 08916, Barcelona, Spain. Phone: 34 93 497 88 94. Fax: 34 93 497 88 95. E-mail: jadomb{at}gmail.com

{triangledown} Published ahead of print on 10 September 2008.

Journal of Clinical Microbiology, November 2008, p. 3660-3667, Vol. 46, No. 11
0095-1137/08/$08.00+0     doi:10.1128/JCM.00618-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Hauck, Y., Fabre, M., Vergnaud, G., Soler, C., Pourcel, C. (2009). Comparison of two commercial assays for the characterization of rpoB mutations in Mycobacterium tuberculosis and description of new mutations conferring weak resistance to rifampicin. J Antimicrob Chemother 64: 259-262 [Abstract] [Full Text]  
  • Huang, W.-L., Chen, H.-Y., Kuo, Y.-M., Jou, R. (2009). Performance Assessment of the GenoType MTBDRplus Test and DNA Sequencing in Detection of Multidrug-Resistant Mycobacterium tuberculosis. J. Clin. Microbiol. 47: 2520-2524 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»